# FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

> **NCT01418222** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 194 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** 5-FU
- **DRUG:** FOLFOX regimen
- **DRUG:** Placebo
- **DRUG:** bevacizumab [Avastin]
- **DRUG:** leucovorin
- **DRUG:** onartuzumab [MetMAb]

## Key facts

- **NCT ID:** NCT01418222
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-14
- **Primary completion:** 2013-03-18
- **Final completion:** 2013-03-18
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2017-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01418222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01418222, "FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01418222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*